Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Valve-in-Valve TAVR for Degenerated Perceval Valves: From Entrapment to Success.

JACC. Case reports·2026
Same author

Obesity is associated with distinct oxylipins in heart failure with preserved ejection fraction.

Metabolomics : Official journal of the Metabolomic Society·2026
Same author

Mechanistic insights and clinical horizons of SGLT2 inhibitors in heart failure management.

Trends in cardiovascular medicine·2025
Same author

Circulating oxylipins predict mortality in heart failure with preserved ejection fraction.

ESC heart failure·2025
Same author

The association of obstructive sleep apnea and complications in patients following implantation of left ventricular assist devices.

Respiratory medicine·2025
Same author

National Trends in Heart Failure and Acute Myocarditis-Related Death Before and During the COVID-19 Pandemic.

Journal of the American Heart Association·2025

Related Experiment Video

Updated: Jun 27, 2026

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography
07:11

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography

Published on: October 28, 2020

Treatment of asymptomatic left ventricular dysfunction.

George V Moukarbel1, Scott D Solomon

  • 1Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

Current Treatment Options in Cardiovascular Medicine
|November 26, 2008
PubMed
Summary

Identifying and treating asymptomatic left ventricular (LV) dysfunction is crucial for preventing heart failure and mortality. Early intervention, particularly neurohormonal blockade for systolic dysfunction, can improve outcomes.

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Experiment Videos

Last Updated: Jun 27, 2026

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography
07:11

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography

Published on: October 28, 2020

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Area of Science:

  • Cardiology
  • Cardiovascular Medicine
  • Clinical Research

Background:

  • Asymptomatic left ventricular (LV) dysfunction, affecting systolic or diastolic function, is prevalent, especially with risk factors like diabetes and hypertension.
  • This condition significantly increases the risk of developing overt heart failure and mortality.
  • Early identification and treatment are vital to prevent disease progression.

Purpose of the Study:

  • To highlight the importance of identifying patients with asymptomatic LV dysfunction.
  • To discuss methods for detecting higher-risk individuals.
  • To review current therapeutic strategies for asymptomatic LV dysfunction.

Main Methods:

  • Clinical assessment, electrocardiography, and natriuretic peptide levels can identify high-risk patients.
  • Echocardiography is a key diagnostic tool for evaluating LV systolic and diastolic function.
  • Review of existing literature on therapeutic interventions for LV dysfunction.

Main Results:

  • Neurohormonal blockade demonstrates positive effects in asymptomatic LV systolic dysfunction, aiding in reversing remodeling and reducing adverse outcomes.
  • Risk factor control is essential for all patients with LV dysfunction.
  • Currently, no specific therapy is recommended for asymptomatic LV diastolic dysfunction beyond risk factor management.

Conclusions:

  • Prompt identification of asymptomatic LV dysfunction is critical for proactive management.
  • Neurohormonal blockade is a cornerstone therapy for asymptomatic LV systolic dysfunction.
  • Further research is needed for effective treatments for asymptomatic LV diastolic dysfunction.